AegirBio AB
ISIN: SE0014401121 | Ticker: AEGIR | LEI: 549300MWGS283WZLYI10
Country: Sweden
AegirBio is a Swedish diagnostics company that was founded to offer tests to monitor and optimize the dosage of biological drugs via its’ unique patented technology platform. Biological drugs are the segment within the pharmaceutical industry where use is growing the fastest.
Meanwhile, drug levels vary enormously (up to 100-fold) in patients receiving standard doses of biological drugs. "One size fits all" results in patients with low drug levels not responding to treatment, while excessive drug levels increase the risk of serious side effects. In approximately 55 percent of cases, this uncertainty in dosing leads to over- or underdosing, which results in unnecessary costs, inadequate results and a higher proportion of patients with severe side effects.
2019
Served areaWorldwide
HeadquartersSölvegatan 43 A, 223 70 Lund – Sweden
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 04.04.23 | Bradley Messmer | Other | Other | SEK 0.00 |
| 16.01.23 | Fredrik Häglund | Other | Other | SEK 85,511.16 |
| 09.12.22 | Raphaela Heussen | Other | Other | SEK 0.00 |
| 27.10.21 | Martin Linde | Other | Other | SEK 0.00 |
| 26.10.21 | Anders Ingvarsson | Other | Other | SEK 0.00 |
| 22.09.21 | Patrik Elfwing | Other | Buy | SEK 519,200.00 |
| 16.09.21 | Anders Ingvarsson | Other | Other | SEK 0.00 |
| 28.06.21 | Gunnar Telhammar | Other | Sell | SEK 47,288.00 |
| 17.06.21 | Fredrik Häglund | Other | Other | SEK 1,840,477.50 |
| 17.06.21 | Martin Linde | Other | Other | SEK 1,169,919.90 |
SE0014401121
LEI549300MWGS283WZLYI10
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.